監管性T細胞療法市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球調節性 T 細胞 (Treg) 療法市場預計將從 2025 年的 27.7 億美元成長到 2031 年的 227.5 億美元，複合年成長率高達 42.04%。

這些治療方法是免疫調節療法，利用特定的CD4+ T細胞亞群來抑制過度免疫反應，主要用於治療自體免疫疾病和移植物抗宿主疾病。該市場的成長主要受全球自體免疫疾病發病率上升以及基於細胞的免疫耐受重建機制所蘊含的巨大臨床潛力的驅動。業界積極的研發活動也進一步推動了這一成長動能。根據國際細胞與基因治療學會（ISCT）預測，到2024年下半年，全球在研細胞和基因療法將達到3063種，顯示市場擁有強勁的投資環境，有利於推動這些療法的進步。

儘管呈現正面趨勢，但市場仍面臨與生產擴充性和複雜性相關的重大障礙。分離、純化和擴增穩定的Treg細胞群所需的複雜流程，導致生產成本高且技術變異性大。這些物流方面的挑戰構成重大障礙，可能延緩Treg細胞的廣泛商業化進程，並限制患者獲得這些先進治療方法。

市場促進因素

推動Treg市場發展的關鍵因素是創業投資和政府資金的湧入，這為支付臨床試驗和生產的高昂成本提供了必要的流動資金。主要產業參與者紛紛獲得大量資金以推進自體免疫疾病治療研發管線，充分證明了這些複雜治療方法的商業性可行性，也印證了這項資金成長動能。例如，Kyverna Therapeutics在2024年2月的新聞稿中宣布，在完成首次股票公開發行（IPO）後，該公司已成功資金籌措3.669億美元，用於支持其基因修飾細胞療法的研發。此類成功案例顯示投資者信心正在全面復甦。根據再生醫學聯盟（Alliance for Regenerative Medicine）報告，光是2024年第一季，全球細胞和基因治療領域就吸引了44億美元的投資，顯示Treg等新型治療方法擁有充足的資金支持。

同時，在幹細胞和實體器官移植中移植物抗宿主疾病（GVHD）發生率的上升，推動了對標靶誘導免疫耐受療法的需求。隨著骨髓惡性腫瘤移植數量的增加，傳統全身性免疫抑制劑的限制促使人們尋求精確的Treg製劑以恢復免疫穩態。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》報告，美國預計將新增62,770例白血病病例，這將形成一個可能需要造血幹細胞移植並面臨高GVHD風險的患者群體。這種臨床負擔迫切需要開發能夠在不損害全身免疫的情況下預防移植物排斥的Treg療法，使其成為移植醫學領域未來重要的替代療法。

市場挑戰

全球調節性T細胞（Treg）療法市場成長面臨的核心挑戰之一是生產過程的複雜性和規模化難度。與標準生物製藥不同，Treg療法需要分離和擴增稀有且具有活性的細胞亞群，這些細胞必須在整個生產週期內保持表現型穩定性和抑制功能。這一複雜過程極易受到技術因素的影響，導致產量不穩定和銷售成本高。因此，這些物流障礙使得研發人員難以將臨床療效轉化為商業性可行的規模化生產，限制了市場滲透率和病患可近性。

這種規模化瓶頸導致商業性成功高度集中，只有少數治療方法能夠克服產業化障礙。生產規模化的高失敗率阻礙了大量候選藥物上市。例如，再生醫學聯盟指出，到2025年，全球先進療法領域約75%的收入將來自少於10種產品。這項數據凸顯了研發活動與商業性現實之間的嚴重脫節，其主要原因是無法有效率地大規模生產Treg等複雜的細胞療法。

市場趨勢

利用嵌合體抗原受體 (CAR) 技術進行精準標標靶化正在革新市場。該技術能夠建構多克隆抗體Treg 更具特異性的工程化 Treg 細胞，從而滿足了在不產生傳統治療方法固有的廣泛免疫抑制的情況下，有效抑制致病性免疫反應的關鍵需求。研發人員正利用這項技術來驗證其在 B 細胞介導的自體免疫疾病中持久的臨床療效。例如，Kyverna Therapeutics 在 2024 年 11 月的新聞稿中宣布，四名接受其 CAR-Tr​​eg 療法 KYV-101 治療的狼瘡性腎炎患者在至少六個月的隨訪期內實現了持續的疾病控制，證實了這種精準療法的持久療效。

同時，製藥公司和生技公司之間透過合作授權協議進行研發的策略整合，正推動早期候選藥物快速轉化為臨床應用。大型製藥企業擴大與專業生物技術公司合作，以獲取專有的Treg平台技術，從而降低細胞療法複雜生產和開發過程中的風險。這一趨勢使得規模較小的開發商能夠利用成熟公司的監管應對力和工業規模來推進其研發管線。 Quell Therapeutics在2024年11月的新聞稿中宣布，該公司在與阿斯特捷利康合作的1型糖尿病項目中成功選定領先候選藥物後，接受了1000萬美元的付款，這凸顯了此類戰略合作的價值，也體現了這一趨勢。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球調節性T細胞（Tregs）療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（自體移植、異體移植）
  • 依應用領域（自體免疫疾病、器官移植、移植物抗宿主疾病（GVHD）等）
  • 依最終使用者（醫院/診所、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美調節性T細胞（Tregs）療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲監管T細胞（Tregs）療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區調節性T細胞（Tregs）療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲調節性T細胞（Tregs）療法的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲調節性T細胞（Tregs）療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球調節性T細胞（Tregs）療法市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Abata Therapeutics
• Atara Biotherapeutics Inc
• Bastion Therapeutics
• Cellenkos, Inc.
• Coya Therapeutics, Inc.
• GentiBio Inc
• Kyverna Therapeutics Inc
• PolTREG SA
• TeraImmune, Inc
• Tr1X TRACT Therapeutics, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Regulatory T-cells (Tregs) Therapies Market is projected to experience substantial growth, expanding from a valuation of USD 2.77 Billion in 2025 to USD 22.75 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 42.04%. These therapies involve immunomodulatory treatments using a specialized subset of CD4+ T cells designed to suppress excessive immune reactions, with a primary focus on treating autoimmune diseases and graft-versus-host disease. The market is fundamentally propelled by the increasing global prevalence of autoimmune disorders and the significant clinical promise of cell-based mechanisms to re-establish immune tolerance. This momentum is further supported by extensive developmental activity within the sector; according to the International Society for Cell & Gene Therapy, the global pipeline included 3,063 cell and gene therapies in the second half of 2024, indicating a robust investment environment driving these advancements.

Despite this positive trajectory, the market confronts a major obstacle regarding manufacturing scalability and complexity. The intricate procedures required to isolate, purify, and expand stable Treg populations entail high production costs and technical variability. These logistical hurdles create significant barriers that could delay widespread commercialization and restrict patient access to these advanced therapies.

Market Driver

A primary catalyst for the advancement of the Treg market is the influx of venture capital and government funding, which provides the necessary liquidity to navigate high clinical trial and manufacturing costs. This financial momentum is illustrated by major industry players securing significant capital to progress their autoimmune pipelines, confirming the commercial viability of these complex therapies. For instance, Kyverna Therapeutics announced in a February 2024 press release regarding the closing of its upsized initial public offering that it successfully raised gross proceeds of $366.9 million to support its engineered cell therapy development. Such corporate successes indicate a broader resurgence in investor confidence, as highlighted by the Alliance for Regenerative Medicine, which reported that the global cell and gene therapy sector attracted $4.4 billion in investment during the first quarter of 2024 alone, demonstrating the deep financial resources available for novel modalities like Tregs.

In parallel, the rising incidence of Graft-Versus-Host Disease (GVHD) in stem cell and organ transplantation is intensifying the demand for targeted tolerance-inducing therapies. As transplant volumes increase to treat blood malignancies, the limitations of traditional systemic immunosuppressants represent a driver for the search for precise Treg formulations capable of restoring immune homeostasis. According to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, there were an estimated 62,770 new leukemia cases in the United States, representing a significant patient population potentially requiring hematopoietic stem cell transplantation and facing high GVHD risks. This clinical burden necessitates the development of Treg therapies that prevent graft rejection without compromising general immunity, positioning them as critical future alternatives in transplant care.

Market Challenge

The central challenge impeding the growth of the Global Regulatory T-cells (Tregs) Therapies Market is the profound difficulty associated with manufacturing complexity and scalability. Unlike standard biologics, Treg therapies require the isolation and expansion of a rare, living cellular subset that must maintain phenotypic stability and suppressive function throughout the production cycle. This complex process is subject to technical variability, leading to inconsistent yields and exorbitant Cost of Goods Sold (COGS). Consequently, these logistical barriers make it incredibly difficult for developers to transition from clinical efficacy to commercially viable mass production, thereby limiting market penetration and patient access.

This scalability bottleneck has created a landscape where commercial success remains highly concentrated, as few therapies can successfully overcome the industrialization barrier. The high failure rate in scaling production prevents the vast pipeline of candidates from reaching the market. For example, the Alliance for Regenerative Medicine noted that in 2025, approximately 75 percent of global revenue in the advanced therapy sector was derived from fewer than 10 products. This statistic underscores the severe disconnect between developmental activity and commercial reality, driven largely by the inability to efficiently manufacture complex cell-based therapies like Tregs at scale.

Market Trends

The integration of Chimeric Antigen Receptor (CAR) technology for precision targeting is fundamentally reshaping the market by enabling the creation of engineered Tregs with specificity that exceeds that of polyclonal counterparts. This shift addresses the critical need for potent suppression of pathogenic immune responses without causing broad immunosuppression, a limitation inherent in earlier modalities. Developers are successfully leveraging this technology to demonstrate durable clinical efficacy in B-cell driven autoimmune conditions; for instance, Kyverna Therapeutics announced in a November 2024 press release that four patients with lupus nephritis treated with the CAR-Treg therapy KYV-101 achieved sustained disease control with at least six months of follow-up, validating the therapeutic endurance of this precision approach.

Simultaneously, the strategic consolidation of R&D through collaborative licensing between pharmaceutical companies and biotech firms is accelerating the translation of early-stage candidates into clinical reality. Large pharmaceutical entities are increasingly partnering with specialized biotech firms to access proprietary Treg platforms, thereby mitigating the risks associated with the complex manufacturing and development of cell therapies. This trend allows smaller developers to leverage the regulatory and industrial scale of established players to advance their pipelines. Highlighting this, Quell Therapeutics announced in a November 2024 press release that it received a $10 million payment from AstraZeneca after successfully selecting a lead candidate for their joint Type 1 Diabetes program, underscoring the value placed on these strategic alliances.

Key Market Players

• Abata Therapeutics
• Atara Biotherapeutics Inc
• Bastion Therapeutics
• Cellenkos, Inc.
• Coya Therapeutics, Inc.
• GentiBio Inc
• Kyverna Therapeutics Inc
• PolTREG S.A.
• TeraImmune, Inc
• Tr1X TRACT Therapeutics, Inc

Report Scope

In this report, the Global Regulatory T-cells (Tregs) Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regulatory T-cells (Tregs) Therapies Market, By Type

• Autologous
• Allogenic

Regulatory T-cells (Tregs) Therapies Market, By Applications

• Autoimmune Diseases
• Organ Transplantation
• Graft-versus-Host Disease (GVHD)
• Others

Regulatory T-cells (Tregs) Therapies Market, By End-User

• Hospitals & Clinics
• Academic & Research Institutions
• Others

Regulatory T-cells (Tregs) Therapies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Regulatory T-cells (Tregs) Therapies Market.

Available Customizations:

Global Regulatory T-cells (Tregs) Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Regulatory T-cells (Tregs) Therapies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Autologous, Allogenic)
  • 5.2.2. By Applications (Autoimmune Diseases, Organ Transplantation, Graft-versus-Host Disease (GVHD), Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Regulatory T-cells (Tregs) Therapies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Applications
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Applications
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Applications
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Applications
      • 6.3.3.2.3. By End-User

7. Europe Regulatory T-cells (Tregs) Therapies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Applications
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Applications
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Applications
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Applications
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Applications
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Applications
      • 7.3.5.2.3. By End-User

8. Asia Pacific Regulatory T-cells (Tregs) Therapies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Applications
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Applications
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Applications
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Applications
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Applications
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Applications
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Regulatory T-cells (Tregs) Therapies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Applications
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Applications
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Applications
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Applications
      • 9.3.3.2.3. By End-User

10. South America Regulatory T-cells (Tregs) Therapies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Applications
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Applications
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Applications
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Applications
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Regulatory T-cells (Tregs) Therapies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abata Therapeutics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Atara Biotherapeutics Inc
• 15.3. Bastion Therapeutics
• 15.4. Cellenkos, Inc.
• 15.5. Coya Therapeutics, Inc.
• 15.6. GentiBio Inc
• 15.7. Kyverna Therapeutics Inc
• 15.8. PolTREG S.A.
• 15.9. TeraImmune, Inc
• 15.10. Tr1X TRACT Therapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer